A Phase 2 trial showed that patients with PTEN-deficient castration-resistant prostate cancer had improved radiographic progression-free survival when treated with a combination of the hormone therapy drug abiraterone and an AKT blocker.115 Although PTEN biomarker testing has been a consideration for standard therapeutic responses, only a limited number of clinical trials plan to determine PTEN status in relation to the clinical response of tumours with ICIs (more details in Table 3). The gene discussed is PTEN; the disease is prostate carcinoma.